For most people, MTHFR gene variants are not clinically significant. Despite widespread online claims linking these common genetic changes to dozens of health problems, major medical organizations recommend against routine MTHFR testing. The American College of Medical Genetics and Genomics has stated that MTHFR polymorphism testing has “minimal clinical utility” and should not be ordered as part of a routine evaluation for blood clotting disorders. The American College of Obstetricians and Gynecologists does not recommend screening for MTHFR variants during pregnancy either.
That said, the story is more nuanced than “it doesn’t matter at all.” The variants do reduce enzyme function, and in certain situations that reduction can contribute to elevated homocysteine levels, which themselves carry health implications. The key distinction is between carrying the gene variant and actually having a measurable problem because of it.
What MTHFR Variants Actually Do
The MTHFR gene provides instructions for making an enzyme that processes folate (vitamin B9) into its active form. Your body uses this active folate to recycle homocysteine, an amino acid, back into methionine. When the enzyme works less efficiently, homocysteine can build up in the blood.
Two variants get the most attention. The C677T variant reduces enzyme activity by about 35% if you carry one copy and roughly 70% if you carry two copies. The A1298C variant is less studied but appears to reduce activity to about 60% of normal in people with two copies. These are not rare mutations. Around 40% of the U.S. population carries at least one copy of C677T, and about 10% carry two copies. The frequency varies by ethnicity: Hispanic populations have the highest prevalence of C677T (42% carry the variant allele), followed by Caucasians (32%) and African Americans (16%).
Carrying these variants doesn’t automatically mean your homocysteine is elevated. Many carriers maintain perfectly normal levels, especially if their folate and B12 intake is adequate. When homocysteine does rise, the clinical threshold starts at roughly 16 micromoles per liter for moderate elevation. People with two copies of C677T can fall into the moderate range (16 to 30) or, less commonly, the intermediate range (31 to 100). Severe elevations above 100 are associated with rare, serious MTHFR deficiency, which is a different condition entirely from carrying common polymorphisms.
Heart Disease and Blood Clots
This is where much of the clinical debate has centered. Elevated homocysteine has long been considered a risk factor for cardiovascular disease and blood clots, so logic suggests that MTHFR variants, which can raise homocysteine, should increase those risks. The evidence doesn’t support that chain of reasoning nearly as well as expected.
A large meta-analysis published in PLOS Medicine examined unpublished datasets (which are less susceptible to publication bias) and found that people with two copies of the C677T variant had essentially the same coronary heart disease risk as those without it. The odds ratio was 1.02, meaning virtually no increased risk. Previously published smaller studies had suggested a 15% increase, but the authors attributed that discrepancy to publication bias and methodological problems in those earlier papers.
The blood clot story is similar. While elevated homocysteine is recognized as a risk factor for deep vein thrombosis and pulmonary embolism, the MTHFR variant itself does not appear to be an independent risk factor. A study of over 4,300 patients with deep vein thrombosis and pulmonary embolism found that the MTHFR gene variant was not a risk factor for venous blood clots. Even among those with the highest-risk genotype (two copies of C677T), the variant was not shown to predict disease recurrence. This is a crucial distinction: elevated homocysteine matters, but having the gene variant that can raise homocysteine is not the same thing as having elevated homocysteine.
Pregnancy and Neural Tube Defects
Folate’s role in preventing neural tube defects like spina bifida is well established, which naturally raises questions about whether impaired folate processing creates pregnancy risks. While some early studies suggested a link between maternal MTHFR status and neural tube defects, the evidence has not been strong enough for professional organizations to act on it. ACOG does not recommend MTHFR screening as a way to assess neural tube defect risk. Standard prenatal folate supplementation remains the recommended approach regardless of MTHFR status.
Depression and Mental Health
Claims that MTHFR variants cause depression or impair antidepressant response are common in alternative health circles. The research paints a more modest picture. Low folate levels have been associated with poorer response to antidepressants and increased risk of depressive relapse. However, a study examining whether MTHFR C677T status affected response to the SSRI fluoxetine found no significant difference. Response rates were 47% for people without the variant and 46% for carriers. All comparisons between genetic groups, including remission rates and depression score improvements, were statistically nonsignificant.
Some preliminary research has explored links between MTHFR variants and conditions like autism and ADHD, but the evidence is far from conclusive. The C677T variant has appeared more frequently in some studies of autistic individuals and their mothers, but autism involves complex interactions between many genes and environmental factors. No direct causal link has been established.
What Actually Matters: Homocysteine, Not Genotype
The consistent theme across the research is that what matters clinically is your actual homocysteine level and folate status, not your MTHFR genotype. Two people with the same MTHFR variant can have completely different homocysteine levels depending on their diet, B vitamin intake, kidney function, and other genetic factors. Testing homocysteine directly is cheaper, more informative, and more actionable than genotyping MTHFR.
If your homocysteine is elevated, the practical response is straightforward: increase your folate and B12 intake. This is true whether or not you carry an MTHFR variant.
Methylfolate vs. Folic Acid
One area where MTHFR status may have practical relevance is in choosing the form of folate supplementation. Standard folic acid is synthetic and needs to be converted by the MTHFR enzyme into its active form. Research shows that about 86% of folic acid reaching the liver remains unmetabolized. For people with reduced MTHFR function, this conversion bottleneck could be meaningful.
Methylfolate (5-MTHF), the already-active form of folate, bypasses this conversion step entirely. Studies have confirmed that methylfolate absorption is not affected by MTHFR gene status. In one study of people with two copies of C677T, methylfolate supplementation produced a sustained reduction in homocysteine levels that persisted six months after stopping treatment, with significantly lower homocysteine levels compared to those who had taken folic acid. Pregnant women supplemented with methylfolate also achieved higher blood folate levels than those taking the same dose of folic acid.
This doesn’t mean folic acid is useless for MTHFR carriers. Many people with these variants process folic acid well enough to maintain normal homocysteine. But if you know you carry two copies of C677T and your homocysteine runs high despite folic acid supplementation, switching to methylfolate is a reasonable step.
Why MTHFR Testing Gets Ordered Anyway
If major guidelines recommend against it, why do so many people end up with MTHFR results in hand? Several factors drive this. Direct-to-consumer genetic testing through services like 23andMe reports MTHFR status as part of broader panels. Some integrative and functional medicine practitioners order the test routinely. And once patients learn they carry a variant, the abundance of alarming (and often inaccurate) online content can create significant anxiety.
The core problem with MTHFR testing in isolation is that it identifies a genetic variant present in roughly half the population without telling you whether it’s actually causing a problem in your body. A homocysteine blood test does that far more directly. If homocysteine is normal, the MTHFR variant is functionally irrelevant regardless of how many copies you carry.